Prescription Drugs Market Research Reports & Industry Analysis
The prescription drugs industry is a key cornerstone of healthcare, delivering vital medications that improve and save lives. As this industry continues to evolve, understanding its nuances can be an ongoing challenge. MarketResearch.com provides hundreds of authoritative prescription drugs market research reports to help stakeholders understand the shifting market landscape and devise effective business strategies.
The Latest Prescription Drugs Market Analysis
- We provide data-packed reports on a wide range of product types, therapeutic areas, regions, and companies.
- Our research includes in-depth analyses of prescription drug market size, growth forecasts, and drivers and challenges.
- In addition, we cover the rise of personalized medicine and gene therapies, as well as regulatory issues and pricing models.
Your Dedicated Research Partner
As the prescription drugs industry shifts and changes, MarketResearch.com equips you with the tools to thrive. Trusted for decades as a reliable research partner, our clients include top pharmaceutical companies, investment banks, and universities. Whether you are exploring new markets or seeking to futureproof your business, our prescription drugs industry research reports offer a wealth of knowledge to inform your strategy. Get started by exploring our vast selection of reports on the prescription drugs industry today.
Prescription Drugs Industry Research & Market Reports
-
Infertility Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis ... Read More
-
Injectable Drugs Delivery
... at a CAGR of 10.1% over the analysis period 2024-2030. Devices, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$1.4 Trillion by the end of the ... Read More
-
Lipid Disorder Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.1 Billion While China is Forecast to Grow at 9.2% CAGR The Lipid Disorder Treatment market in the U.S. ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis period. ... Read More
-
Doxorubicin
... 5.8% over the analysis period 2024-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth ... Read More
-
Immunosuppressants
... 13.8% over the analysis period 2024-2030. Calcineurin Inhibitors, one of the segments analyzed in the report, is expected to record a 15.9% CAGR and reach US$38.5 Billion by the end of the analysis period. Growth ... Read More
-
Canine Atopic Dermatitis
... at a CAGR of 8.2% over the analysis period 2024-2030. Glucocorticoids, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.0 Billion by the end of the ... Read More
-
Coating Agents
... CAGR of 7.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$333.0 Million While China is Forecast to Grow at 10.5% CAGR The Coating Agents market in the U.S. is estimated at ... Read More
-
Herpes Zoster Treatment
... at a CAGR of 1.9% over the analysis period 2024-2030. Antiviral Medications, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$134.0 Million by the end of ... Read More
-
Impetigo Drugs
... CAGR of 4.4% over the analysis period 2024-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$883.5 Million by the end of the analysis ... Read More
-
Immunomodulators
... 5.7% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$209.8 Million by the end of the analysis period. Growth in ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end of ... Read More
-
Somatostatin Analogs
... CAGR of 5.9% over the analysis period 2024-2030. Octreotide, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.0 Billion by the end of the analysis period. ... Read More
-
Prescription Drugs
... CAGR of 5.7% over the analysis period 2024-2030. Generics, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More
-
Multiple Myeloma Therapeutics
... at a CAGR of 14.5% over the analysis period 2024-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$37.6 Billion by the ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Herpes Simplex Virus Infections
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR The Herpes Simplex Virus Infections market ... Read More
-
e-Prescription Systems
... CAGR of 16.7% over the analysis period 2024-2030. Solutions, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$3.2 Billion by the end of the analysis period. ... Read More
-
Kidney Cancer Drugs
... at a CAGR of 4.8% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$5.6 Billion by the end of ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Gamma Oryzanol
... growing at a CAGR of 5.5% over the analysis period 2024-2030. Sports Supplement, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach 11.3 Thousand Tons by the ... Read More
-
Medication Management Systems
... at a CAGR of 9.9% over the analysis period 2024-2030. Inventory Management Solutions, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$2.2 Billion by the end ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Opioids
... 2.3% over the analysis period 2024-2030. Extended-Release / Long-Acting, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$18.7 Billion by the end of the analysis period. ... Read More
Research Assistance
